Ebewe Pharma

Activities: Manufacturing Hi Tech Manufacturing

Trending Articles

  1. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to...
  2. The IND advantage: why early derisking is a strategic imperative for complex biologics As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating...
  3. Redefining safety, efficiency, and sustainability: SCHOTT Pharma launches next generation polymer syringe system A new cap design for prefillable polymer syringes provides tamper evidence at the individual syringe level, significantly reducing the risk of drug waste and ensuring patient...
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic...
  5. Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and...

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

Related Content

Pharmaceutical

Brussels approves acquisition of Ebewe by Novartis

<p>The European Commission has granted competition approval to the takeover of Austria's generic pharmaceuticals company Ebewe SP by Swiss drugmaker Novartis, enabling the Euro 1.3bn deal to go ahead. Although Novartis makes generic medicines through its Sandoz division, the EC concluded that the deal &quot;would not significantly impede effective competition&quot; in Europe. </p>
Media

Novartis to add EBEWE Pharma generic injectables business to Sandoz division

<p>Novartis is to acquire the generic injectables business of Austrian company EBEWE Pharma for Euro 925m (US$1.2bn), providing its Sandoz generic pharmaceuticals division with an opportunity to grow while improving access to many generic oncology medicines.</p>
Subscribe now